SP1 and metabolic dysfunction-associated steatohepatitis: Activation of IGF1, TGF-β and Wnt/β-catenin signaling, NRIP1, Nrf2, SREBP-LXRα, PI3K/AKT, CMYC, CEBPβ, transcriptional factor SP1, NFκB, IL1B and IL6, VEGFA, EGF, FGF2 and other upstream regulators, and downregulation of PPARs and p53 was predicted to be associated with NASH (Figure 3).